NASDAQ:XBIT XBiotech (XBIT) Stock Forecast, Price & News $5.45 -0.05 (-0.91%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$5.30▼$5.6350-Day Range$3.06▼$5.7652-Week Range$3.00▼$6.49Volume54,674 shsAverage Volume207,301 shsMarket Capitalization$165.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About XBiotech (NASDAQ:XBIT) StockXBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.Read More Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIT Stock News HeadlinesJune 3, 2023 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Coverage Initiated at StockNews.comMay 30, 2023 | americanbankingnews.comXBiotech Inc. (NASDAQ:XBIT) Short Interest Up 23.1% in MayJune 10, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 29, 2023 | americanbankingnews.comXBiotech (NASDAQ:XBIT) and Cue Biopharma (NASDAQ:CUE) Financial ComparisonMay 23, 2023 | finanznachrichten.deXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 22, 2023 | finance.yahoo.comFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 19, 2023 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Now Covered by StockNews.comMay 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesJune 10, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 17, 2023 | finance.yahoo.comXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 10, 2023 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Coverage Initiated by Analysts at StockNews.comApril 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 17, 2023 | finance.yahoo.comXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 9, 2023 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are individual investors with 51% stake, while 36% is held by insidersApril 5, 2023 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Now Covered by Analysts at StockNews.comMarch 26, 2023 | americanbankingnews.comStockNews.com Upgrades XBiotech (NASDAQ:XBIT) to "Hold"February 15, 2023 | finance.yahoo.comThe past three years for XBiotech (NASDAQ:XBIT) investors has not been profitableNovember 11, 2022 | finance.yahoo.comXBiotech Third Quarter 2022 Earnings: US$0.42 loss per share (vs US$0.11 loss in 3Q 2021)October 31, 2022 | finance.yahoo.comInsiders own 35% of XBiotech Inc. (NASDAQ:XBIT) shares but individual investors control 47% of the companyOctober 18, 2022 | prnewswire.comHelicobacter pylori Infection Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2022-2032) | DelveInsight - PR NewswireOctober 13, 2022 | finance.yahoo.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - Yahoo FinanceOctober 13, 2022 | globenewswire.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer - GlobeNewswireOctober 13, 2022 | finance.yahoo.comXBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerSeptember 8, 2022 | finance.yahoo.comXBiotech (NASDAQ:XBIT) shareholders have endured a 73% loss from investing in the stock a year agoSeptember 2, 2022 | nasdaq.comWe Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - NasdaqAugust 14, 2022 | finance.yahoo.comWe Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Yahoo FinanceAugust 10, 2022 | marketscreener.comXBIOTECH INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) | MarketScreener - Marketscreener.comSee More Headlines XBIT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIT Company Calendar Today6/10/2023Next Earnings (Estimated)6/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XBIT CUSIPN/A CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees97Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,900,000.00 Net Margins-820.45% Pretax Margin-882.82% Return on Equity-12.81% Return on Assets-12.46% Debt Debt-to-Equity RatioN/A Current Ratio59.78 Quick Ratio59.78 Sales & Book Value Annual Sales$4.01 million Price / Sales41.37 Cash FlowN/A Price / Cash FlowN/A Book Value$7.90 per share Price / Book0.69Miscellaneous Outstanding Shares30,440,000Free Float21,794,000Market Cap$165.90 million OptionableOptionable Beta1.21 Key ExecutivesJohn SimardChairman, President & Chief Executive OfficerAshley OteroVice President-Clinical OperationsAngela HuChief Financial & Accounting OfficerSushma ShivaswamyChief Scientific OfficerMark ZiatsMedical DirectorKey CompetitorsAnnexonNASDAQ:ANNXLarimar TherapeuticsNASDAQ:LRMRPuma BiotechnologyNASDAQ:PBYIMerrimack PharmaceuticalsNASDAQ:MACKCue BiopharmaNASDAQ:CUEView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 38,163 shares on 5/16/2023Ownership: 0.125%Two Sigma Investments LPSold 11,099 shares on 5/15/2023Ownership: 0.180%Two Sigma Advisers LPSold 11,700 shares on 5/15/2023Ownership: 0.157%Dimensional Fund Advisors LPSold 7,272 shares on 5/12/2023Ownership: 0.247%Bank of America Corp DESold 4,624 shares on 5/12/2023Ownership: 0.046%View All Institutional Transactions XBIT Stock - Frequently Asked Questions How have XBIT shares performed in 2023? XBiotech's stock was trading at $3.51 at the start of the year. Since then, XBIT shares have increased by 55.3% and is now trading at $5.45. View the best growth stocks for 2023 here. When is XBiotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 13th 2023. View our XBIT earnings forecast. What is John Simard's approval rating as XBiotech's CEO? 20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ). When did XBiotech IPO? (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO. What is XBiotech's stock symbol? XBiotech trades on the NASDAQ under the ticker symbol "XBIT." Who are XBiotech's major shareholders? XBiotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.25%), Connor Clark & Lunn Investment Management Ltd. (0.19%), Two Sigma Investments LP (0.18%), Renaissance Technologies LLC (0.17%), Two Sigma Advisers LP (0.16%) and Susquehanna International Group LLP (0.13%). Insiders that own company stock include John Simard, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie. View institutional ownership trends. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is XBiotech's stock price today? One share of XBIT stock can currently be purchased for approximately $5.45. How much money does XBiotech make? XBiotech (NASDAQ:XBIT) has a market capitalization of $165.90 million and generates $4.01 million in revenue each year. The biopharmaceutical company earns $-32,900,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. How can I contact XBiotech? XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The official website for the company is www.xbiotech.com. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at swhitehurst@xbiotech.com, or via fax at 512-386-5505. This page (NASDAQ:XBIT) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.